Prime Medicine, Inc.
Expected move
InputsNext report
Last report
Largest filed tie
13F top-10 QoQ
Top fund weight
Last report0 of 8 at or beyond impliedshaded = implied▲▼ = realized× = |realized| ÷ implied
−4.22%
vs ±14.2% implied · ×0.30
shaded = implied · ▲▼ = realized
Prime Medicine has 9 disclosed suppliers and 3 disclosed customers in SEC filings.
Prime Medicine, Inc.
4.72
−0.52 · −9.92%
post 4.71 −0.21%
SentenceUnder our license and collaboration agreement with Beam, or the Beam Collaboration Agreement, each party grants to the other certain exclusive and non-exclusive licenses and rights to certain Prime Editing, CRISPR and delivery technologies for use in certain specified fields.
SentenceOur compensation committee has engaged Alpine Rewards, LLC, or Alpine Rewards, as its independent compensation consultant.
PRME 10-Kaccession 0001628280-26-013569
SentenceUnder the amended Broad License Agreement and the 2022 Broad License Agreement, Broad Institute grants us certain rights and licenses under certain patent rights it owns or controls relating to our Prime Editing technology and product candidates.
PRME 10-Kaccession 0001628280-26-013569
SentenceIn July 2025, Dr. Duffield entered into the Duffield Consulting Agreement with us, pursuant to which Dr. Duffield will provide advice and assistance in the area of his expertise.
PRME 10-Kaccession 0001628280-26-013569
SentenceIn May 2025, pursuant to the Gottesdiener Separation Agreement and Gottesdiener Employment Agreement, we entered into an advisory services agreement with Dr. Gottesdiener, or the Gottesdiener Advisor Agreement, to retain certain non-exclusive, limited consulting and advisory services of Dr. Gottesdiener for a period of up to one year from the date of his separation.
PRME 10-Kaccession 0001628280-26-013569
SentenceDr. Liu's laboratory at Broad Institute developed engineered pegRNAs, or epegRNAs, which we have exclusively in-licensed.
PRME 10-Kaccession 0001628280-26-013569
SentencePursuant to an advisory services agreement with Jeffrey Marrazzo, a member of our board of directors, or the Marrazzo Agreement, dated February 29, 2024, Mr. Marrazzo agreed to provide certain professional services to the Company separate from and in addition to his service as a member of our board of directors, and we agreed to pay Mr. Marrazzo an annual fee of $50,000 per year in addition to the grant of an option to purchase 250,000 shares of the Company's common stock.
PRME 10-Kaccession 0001628280-26-013569
SentenceIn May 2025, pursuant to the Gottesdiener Separation Agreement and Gottesdiener Employment Agreement, we entered into a consulting agreement with KMG Strategic Consulting, LLC, or the KMG Consulting Agreement, a limited liability company managed by Dr. Gottesdiener, to provide for Dr. Gottesdiener's continued consulting services to us.
PRME 10-Kaccession 0001628280-26-013569
SentencePricewaterhouseCoopers LLP, or PwC, served as independent registered public accounting firm for our Company with respect to the audit of the Company's consolidated financial statements for the fiscal year ended December 31, 2025
PRME 10-Kaccession 0001628280-26-013569
SentenceFor example, we issued and sold 11,006,163 shares of our common stock to BMS as part of the BMS Collaboration Agreement.
Sentence• $12.0 million of proceeds received under the CFF Agreement.
PRME 10-Kaccession 0001628280-26-013569
Linked news
Expected move
Inputs8Q avg ±7.5%·×1.65·rich
straddle ±20.7%
spot 4.72exp Nov 20ATM strike 4.5ATM straddle 1.15IV 129%